Research in bone marrow transplant patients with blood cancers and febrile neutropenia suggests the host-response test may help identify infection in high-risk populations.
The CDC has named Cepheid one of four national collaborators to accelerate rapid diagnostic assay development for public health emergencies under a new federal initiative and IDIQ contract.
A longitudinal study finds blood-based biomarkers more sensitive than PET scans in detecting obesity's impact on Alzheimer's pathology.
The CLIA-certified facility offers functional precision medicine testing that analyzes live tumor cells against FDA-approved therapies within 10 days.
The 3-test panel detects antibodies for parasitic infections that affect up to 45 million people globally and are linked to bile duct cancer.
PD-L1 testing is now cleared to help identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for anti–PD-1 therapy.
The test is being developed to differentiate between adenoviral conjunctivitis, herpetic keratitis, and allergic conjunctivitis at the point of care.
The test measures two sugar alcohols to detect SORD-related neuropathy, which standard genetic tests sometimes miss.
The Elecsys pTau-181 test helps primary care clinicians rule out Alzheimer's disease in symptomatic patients aged 55 and older.
Babson Diagnostics’ BetterWay GLP-1 blood testing panel is now available at more than 25 Austin and Temple, Texas, retail locations, including Sam’s Club and Peoples Rx pharmacies. The panel features 29 tests to support GLP-1 therapy.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The eight-minute test also shortened hospital stays by nearly two days at Froedtert Hospital, reinforcing previous multi-site evidence.